LOGIN
ID
PW
MemberShip
2025-09-04 12:54
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Reimb listing approved for the first generic of 'Angeliq'
by
Lee, Tak-Sun
Aug 27, 2025 06:07am
The first generic of Angeliq Tab (drospirenone¡¤estradiol, Bayer), a hormone-based medicine for use in postmenopausal women, will be included in the reimbursement listing. Analysis suggests that the commercialization of domestically produced generic is significant, considering that there had been supply issues related to Angeliq, which is
Company
Jaypirca¡¯s reimbursement imminent in Korea
by
Eo, Yun-Ho
Aug 27, 2025 06:07am
The BTK inhibitor Jaypirca is likely to be listed for reimbursement soon. According to Dailypharm coverage, the National Health Insurance Service (NHIS) and Lilly Korea recently completed price negotiations for Jaypirca (pirtobrutinib), a treatment for relapsed or refractory mantle cell lymphoma (MCL). As a result, Jaypirca¡¯s reimburs
Company
Targeted therapies and antibody drugs enter clinical trials
by
Son, Hyung Min
Aug 27, 2025 06:07am
Korea¡¯s pharmaceutical and biotech industry is accelerating new drug development for pancreatic cancer, a cancer regarded as one of the most intractable cancers. Onconic Therapeutics, Prestige Biopharma, and Aptamer Sciences have each started clinical trials, making their bid into the field. The company plans to test the commercial viability of
Company
Co-promotion discussed for the diabetes drug Mounjaro
by
Kim, Jin-Gu
Aug 27, 2025 06:07am
The possibility of a co-promotion partnership between Eli Lilly and Korean pharmaceutical companies for 'Mounjaro,' the treatment of diabetes and obesity, continues to be discussed. While Lilly Korea officially maintains a 'direct sales' policy, it is reported that they are also conducting undiscloed discussions for potential partnerships.
Policy
¡®80,000 Wegovy prescriptions issued per month¡¯
by
Lee, Jeong-Hwan
Aug 27, 2025 06:06am
The popular obesity drug Wegovy, which was launched in Korea in October last year, has already been prescribed about 400,000 times within eight months, raising concerns over potential misuse and abuse. On the 25th, Rep. Kim Sun-min of the Rebuilding Korea Party disclosed the ¡®Annual and Monthly Status of Wegovy Prescriptions based on DUR
Company
CKD aims at developing next-generation¡¤new anti-cancer drug
by
Son, Hyung Min
Aug 26, 2025 06:06am
Chong Kun Dang is speeding up investment in the new anti-cancer drug sector. The company aims to commercialize anti-cancer drugs by advancing its in-house pipelines for Antibody-Drug Conjugates (ADCs) and Cell and Gene Therapies (CGTs). Additionally, Chong Kun Dang is securing domestic rights for new drugs, including Chimeric Antigen Receptor T-
Policy
MFDS will intensively monitor Wegovy and other obesity drugs
by
Lee, Hye-Kyung
Aug 26, 2025 06:05am
The Ministry of Food and Drug Safety (MFDS) has designated ¡®Wegovy¡¯ and other GLP-1-class obesity injectables as targets for intensive monitoring and plans to continuously monitor side effects in collaboration with the Korea Institute of Drug Safety & Risk Management. Th MFDS designates the intensive monitoring status to drugs with high
Company
Expanded indication for Kisqali in early breast cancer
by
Son, Hyung Min
Aug 26, 2025 06:05am
On August 22, Novartis Korea (CEO and President Byeong-jae Yoo) announced that its CDK 4/6 inhibitor, Kisqali, was approved for a new indication from the Ministry of Food and Drug Safety for use as an adjuvant therapy in patients with HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative) Stage II and III e
Company
Will companies pass Korea due to Trump¡¯s drug price reform?
by
Moon, sung-ho
Aug 26, 2025 06:05am
Since Trump took office, the US has designated the pharmaceutical industry as its core strategic industry and is working to reshape the industry with the US at its center. The goal is to significantly lower drug prices in the U.S., the world's largest pharmaceutical market. However, the ¡°Most-Favored-Nation Pricing (MFN)¡± policy recently a
Company
Expanded competitiveness of K-Bio immunotherapies
by
Son, Hyung Min
Aug 26, 2025 06:05am
Korean pharmaceutical and biotech companies are entering the development of immunotherapies, increasing the possibility of 'big deals' with global pharmaceutical companies. As competition for new drugs targeting next-generation immune checkpoint proteins intensifies, Aprogen has begun developing VISTA targets by securing an antibody candidate fr
1
2
3
4
5
6
7
8
9
10
>